Abstract
Adenosine is a neuromodulator that interacting with four receptors, A1, A2A, A2B and A3, is involved in the regulation of several biological functions in different organs and tissues, including the central nervous system, the cardiovascular system and the airways; many pathophysiological states are associated with changes of adenosine levels. For these reasons pharmaceutical companies and academicians performed intense efforts to obtain agonists, antagonists and allosteric enhancers selective for each adenosine receptor subtypes as potential clinical candidates. In fact, therapeutic modulation of the adenosine system could offer the possibility of a “soft” treatment of different diseases, but, due to the ubiquitous distribution of adenosine and of its receptors, the challenge in therapy development depends from specificity for the different receptor subtypes. Some A1 agonists and antagonists, very potent and selective, reached clinical trials for the treatment of different diseases. A1 agonists are clinical candidates for atrial arrhythmias, angina, type 2 diabetes and in pain management, while A1 antagonists are in study as potassium-sparing diuretics with kidney-protecting properties and in chronic heart diseases. Several reviews, recently published and herein cited, reported in detail the biological and clinical aspects of such molecules. This review focuses on the A1 adenosine receptor (A1AR) ligands, both agonists and antagonists, appeared in the literature in the last few years, together with their potential therapeutic application, pointing the attention on their chemical structures and SAR (Structure Activity Relationship) and also reporting new findings on preclinical or clinical trials of some important A1AR ligands synthesized in the past.
Keywords: Adenosine, A1 receptor, agonists, antagonists, SAR, heterocyclic compounds
Current Topics in Medicinal Chemistry
Title: A1 Receptors Ligands: Past, Present and Future Trends
Volume: 10 Issue: 9
Author(s): S. Schenone, C. Brullo, F. Musumeci, O. Bruno and M. Botta
Affiliation:
Keywords: Adenosine, A1 receptor, agonists, antagonists, SAR, heterocyclic compounds
Abstract: Adenosine is a neuromodulator that interacting with four receptors, A1, A2A, A2B and A3, is involved in the regulation of several biological functions in different organs and tissues, including the central nervous system, the cardiovascular system and the airways; many pathophysiological states are associated with changes of adenosine levels. For these reasons pharmaceutical companies and academicians performed intense efforts to obtain agonists, antagonists and allosteric enhancers selective for each adenosine receptor subtypes as potential clinical candidates. In fact, therapeutic modulation of the adenosine system could offer the possibility of a “soft” treatment of different diseases, but, due to the ubiquitous distribution of adenosine and of its receptors, the challenge in therapy development depends from specificity for the different receptor subtypes. Some A1 agonists and antagonists, very potent and selective, reached clinical trials for the treatment of different diseases. A1 agonists are clinical candidates for atrial arrhythmias, angina, type 2 diabetes and in pain management, while A1 antagonists are in study as potassium-sparing diuretics with kidney-protecting properties and in chronic heart diseases. Several reviews, recently published and herein cited, reported in detail the biological and clinical aspects of such molecules. This review focuses on the A1 adenosine receptor (A1AR) ligands, both agonists and antagonists, appeared in the literature in the last few years, together with their potential therapeutic application, pointing the attention on their chemical structures and SAR (Structure Activity Relationship) and also reporting new findings on preclinical or clinical trials of some important A1AR ligands synthesized in the past.
Export Options
About this article
Cite this article as:
Schenone S., Brullo C., Musumeci F., Bruno O. and Botta M., A1 Receptors Ligands: Past, Present and Future Trends, Current Topics in Medicinal Chemistry 2010; 10 (9) . https://dx.doi.org/10.2174/156802610791268729
DOI https://dx.doi.org/10.2174/156802610791268729 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Immunologic Considerations in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Thoughtful Insights into the Therapeutic Armamentarium of Chalcones: 10 Years of Glorious Journey
Current Bioactive Compounds Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
Current Pharmaceutical Design Editorial [ Advanced Glycation End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi ]
Current Pharmaceutical Design Menopause, A Universal Female Experience: Lessons from Mexico and Central America
Current Women`s Health Reviews Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Current Pharmaceutical Design A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Extracellular Matrix Remodeling in Hypertension
Current Hypertension Reviews The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research Coronary Angiography Using Noninvasive Imaging Techniques of Cardiac CT and MRI
Current Cardiology Reviews Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Lipoprotein(a) Management: Pharmacological and Apheretic Treatment
Current Medicinal Chemistry